 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...5051525354555657585960...123124» |
- | sorafenib / Generic mfg.
Journal: Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function. (Pubmed Central) - Sep 3, 2022
P3
Results suggest that patients with uHCC whose liver function deteriorates to CP-B after initiation of therapy may continue to receive lenvatinib. ClinicalTrials.gov, NCT01761266, https://clinicaltrials.gov/ct2/show/NCT01761266.
- || Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche
Retrospective data, Review, Journal: Safety of endoscopy in patients undergoing treatments with antiangiogenic agents: A 5-year retrospective review. (Pubmed Central) - Sep 3, 2022
ClinicalTrials.gov, NCT01761266, https://clinicaltrials.gov/ct2/show/NCT01761266. As per this single center retrospective study, the rate of endoscopic procedure-related adverse events and death within 28 d of AA administration appears to be low.
- | Journal, PD(L)-1 Biomarker, IO biomarker: Interdisciplinary recommendations for the treatment of advanced renal cell carcinoma (Pubmed Central) - Sep 3, 2022
Furthermore, the combination of lenvatinib + everolimus and axitinib are approved treatment options in the second line and further settings...As in previous years, the experts intended to provide recommendations for clinical practice. The results are presented in this publication.
- || Imfinzi (durvalumab) / AstraZeneca, lenvatinib / Generic mfg., sorafenib / Generic mfg.
خيارات أخرى: ٣) Durvalumab + Tremilimumab ٤) Durvalumab ٥) Sorafenib ٦) Lenvatinib معظم الخيارات أعلاه متاحة في جميع مراكز علاج الأورام التخصصية في المملكة (Twitter) - Sep 3, 2022
- | Enrollment open: International Multicentric Study ARON-1 (clinicaltrials.gov) - Sep 2, 2022
P=N/A, N=1220, Recruiting, Sponsor: Hospital of Macerata
The results are presented in this publication. Not yet recruiting --> Recruiting
- |||| Review: @ILCAnews Drs. Tim Meyer @ucl and Katie Kelley @UCSFMedicine review the current state of #HCC systemic therapy #sorafenib #lenvatinib #cabozantinib #pembrolizumab #atezolizumab #bevacizumab #durvalumab #tremelimumab #camrelizumab #tislelizumab #rivoceranib #ilca22 (Twitter) - Sep 2, 2022
- || lenvatinib / Generic mfg.
P2 data, Clinical Trial,Phase II, Journal: Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). (Pubmed Central) - Sep 2, 2022
Although the number of responders was small, responses were durable, indicating that lenvatinib may be beneficial for selected patients. Further investigation to identify suitable candidates for lenvatinib monotherapy is needed.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Health-Related Quality of Life in Patients With Advanced or Recurrent Endometrial Cancer Who Have Disease Progression on or Following Prior Treatment With a Platinum-Containing Therapy: Analysis of EQ-5D Utility Scores (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2430;
AEs, disease progression, and time to death were associated with significant deteriorations in quality of life in patients with advanced EC following prior platinum-based systemic therapy. These findings will support future economic evaluations of treatments in advanced EC.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Cost-Effectiveness of Pembrolizumab+Lenvatinib for Treatment of Advanced Endometrial Carcinoma in Women Who Have Progressed Following Prior Systematic Therapy and Are Not Candidates for Curative Surgery or Radiation in France (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1890;
A three-state partitioned survival model (pre-progression, post-progression and death) was developed to estimate costs, effectiveness, and incremental cost-effectiveness ratio (ICER) of pembrolizumab + lenvatinib versus chemotherapy (doxorubicin or paclitaxel). Model-based analysis suggests that pembrolizumab + lenvatinib improves life expectancy and is likely to be cost-effective versus chemotherapy for treatment of advanced endometrial carcinoma in women who have progressed following prior systematic therapy and are not candidate for curative surgery or radiation in France, assuming a WTP under 160,000€/QALY.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
A Systematic Literature Review (SLR) of the Clinical Evidence for Treatment of Differentiated Thyroid Cancer (DTC) After Prior Systemic Therapy (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1003;
Evaluated interventions and outcomes were heterogenous, suggesting no specific standard-of-care treatment; consistent with clinical guidelines at the time the research was conducted. The lack of 2L therapy options shows significant unmet need for treatments with novel mechanisms of action that demonstrate clinical benefit in patients with RAI-refractory DTC.
- Comparing Survival Extrapolation Outcomes Using Different Network Meta-Analyses (NMA) Methods: An Application in Patients With Metastatic Renal Cell Carcinoma (MRCC) Treated With Immunotherapy (IO) Based Combinations (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_903;
Different NMA methods can lead to significantly different survival outcomes. The appropriate NMA method should be selected carefully to avoid biased estimates in health economic models used for reimbursement decision-making.
- | Retrospective data, Journal: Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. (Pubmed Central) - Aug 31, 2022
Chylous effusions can emerge during treatment with selected RET TKIs. Recognition of this side effect is key to prevent potential misattribution of worsening effusions to progressive malignancy.
- | lenvatinib / Generic mfg.
Journal: The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma. (Pubmed Central) - Aug 31, 2022
Decreased NO levels were associated with the occurrence of AEs and worse prognosis after lenvatinib administration. Change rate in serum NO can be used as predictive markers in patients receiving lenvatinib therapy for HCC.
- Keytruda (pembrolizumab) / Merck (MSD)
PRIMER-1: A RANDOMISED PHASE II TRIAL OF PERIOPERATIVE PEMBROLIZUMAB AND LENVATINIB IN RESECTABLE HEPATOCELLULAR CARCINOMA (HCC) () - Aug 31, 2022 - Abstract #ILCA2022ILCA_242;
J Clin Oncol. 2020 Sep 10; 38(26):2960-2970.
- lenvatinib / Generic mfg., sorafenib / Generic mfg.
SPONTANEOUSLY RUPTURED HEPATOCELLULAR CARCINOMA ON NON-CIRRHOTIC LIVER: TREATMENT AND PROGNOSIS. () - Aug 31, 2022 - Abstract #ILCA2022ILCA_234;
In non-cirrhotic patients with HCC, 5% presented with hemoperitoneum secondary to HCC rupture. 2.
- lenvatinib / Generic mfg.
IMPACT OF DOSE ADJUSTMENT ON CLINICAL OUTCOME OF LENVATINIB-TREATED PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) () - Aug 31, 2022 - Abstract #ILCA2022ILCA_228;
Experiences of dose escalation during the treatment is associated with favorable outcomes of lenvatinib. In each clinical visit, clinicians should assess patients' condition and consider dose escalation of lenvatinib if feasible, amongst population who have lower starting dose than the recommended dose at baseline or prior dose reduction during the treatment course.
- Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Tecentriq (atezolizumab) / Roche
EPIDEMIOLOGY, REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES OF SYSTEMIC TREATMENTS IN UNRESECTABLE HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW () - Aug 31, 2022 - Abstract #ILCA2022ILCA_186;
Sorafenib and lenvatinib still remain the most common systemic treatments with some recent studies reporting their early clinical experience with atezolizumab plus bevacizumab therapy. As new treatments for uHCC become available, assessment of real-world clinical effectiveness will be important for assisting clinical decision making
- Keytruda (pembrolizumab) / Merck (MSD)
ASSOCIATION OF RNA SEQUENCING–BASED GENE SIGNATURES AND CLINICAL OUTCOMES OF LENVATINIB (LEN) + PEMBROLIZUMAB (PEMBRO) IN HEPATOCELLULAR CARCINOMA (HCC): RESULTS FROM STUDY 116/KEYNOTE-524 () - Aug 31, 2022 - Abstract #ILCA2022ILCA_153;
P1b
When adjusted for the TcellinfGEP, the RAS signature trended towards improvements in both ORR and PFS, although only PFS was statistically significant. These results need further validation in larger cohorts.
- |||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial, Metastases: MK-7902-010 China Extension: A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension (clinicaltrials.gov) - Aug 31, 2022
P3, N=150, Recruiting, Sponsor: Merck Sharp & Dohme LLC
- | Ibrance (palbociclib) / Pfizer
Journal: Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response. (Pubmed Central) - Aug 30, 2022
Treatment was given at reduced dosing (lenvatinib 10 mg oral daily (approved dose = 24 mg daily)) and palbociclib 75 mg oral daily, one week on and one week off (approved dose = 125 mg oral daily, three weeks on/one week off) and is tolerated well. Therefore, co-targeting the aberrant cyclin and FGFR pathways resulted in long-term exceptional response in a patient with refractory advanced osteosarcoma.
- |||| Ibrance (palbociclib) / Pfizer, lenvatinib / Generic mfg.
Matched combination (lenvatinib + palbociclib) therapy for FGFR and cell cycle-altered osteosarcoma benefits 51+ MONTHS and ONGOING with @Dr_R_Kurzrock @VivekSubbiah! Molecular alterations drive cancer. Slay the hydra, cut off all the heads! https://t.co/fI6RjbvZ9r (Twitter) - Aug 29, 2022
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 29, 2022
P2, N=60, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- || Review, Journal: Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities. (Pubmed Central) - Aug 27, 2022
On the basis of the poor prognoses and the meager benefits deriving from the available systemic therapies, research into new treatments is extremely necessary. In this review, we focus on the available systemic therapies for advanced HCC, with a look toward the future.
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition: The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma. (Pubmed Central) - Aug 27, 2022
Combining TKI and ICI provides an acceptable antitumor efficacy in first-line therapy for advanced-stage HCC patients. The survival outcomes between different TKIs or ICIs display no differences.
- || Review, Journal: Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. (Pubmed Central) - Aug 26, 2022
At the moment, numerous clinical trials in advanced HCC are underway, which will bring continuous change to the management, and increase the survival, for patients with advanced HCC. Our review article: (1) summarizes United States Food and Drug Administration (US FDA) approved systemic therapies in advanced HCC, (2) reports the evidence of currently approved treatments, (3) discusses potential drugs/drug combinations being currently tested in phase III clinical trials, and (4) proposes possible future directions in drug development for advanced HCC.
- ||| lenvatinib / Generic mfg.
Looking forward to see the data of LEAP-002 at ESMO 2022. Press release indicates that Lenvatinib did better then expected... (Twitter) - Aug 26, 2022
- ||| lenvatinib / Generic mfg.
Clinical: In your paper you only analyse 3 pts in CP-B (7) in lenvatinib group, because 5 and 6 points are CP-A!.. (Twitter) - Aug 26, 2022
- || lenvatinib / Generic mfg.
important information regarding what happened in the REFLECT trial.. LEAP trial being neg for OS.. Today if we have a similar situation,CTP A>B,without PD should we consider adding IO to Lenvatinib .. Waiting for PD may be too late for IO treatment for many.. (Twitter) - Aug 26, 2022
- | lenvatinib / Generic mfg.
Retrospective data, Journal: Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma. (Pubmed Central) - Aug 25, 2022
Our review article: (1) summarizes United States Food and Drug Administration (US FDA) approved systemic therapies in advanced HCC, (2) reports the evidence of currently approved treatments, (3) discusses potential drugs/drug combinations being currently tested in phase III clinical trials, and (4) proposes possible future directions in drug development for advanced HCC. TACE-L proves to be a safe and efficacious conversion therapy modality that allows for secondary resectability in patients with initially unresectable ICC.
- | lenvatinib / Generic mfg.
Journal: A case of successful treatment with lenvatinib in primary hepatoid adenocarcinoma of the gallbladder that was difficult to distinguish from hepatocellular carcinoma. (Pubmed Central) - Aug 25, 2022
A total of 9 months has passed since the start of chemotherapy with lenvatinib, and the patient is in good general condition. To establish an effective treatment for primary HAC of the gallbladder, further accumulation and investigation of cases are recommended.
- ||||| lenvatinib / Generic mfg., sorafenib / Generic mfg.
Clinical: 🧐How to proceed with #HCC pts who deteriorate to CP B #livercirrhosis under Sorafenib or Lenvatinib❓ @TAMedOncol https://t.co/F4jTAzHGVP… 📢We just published data from REFLECT phs-III 👉Continuation of systemic therapy is a viable option❗️ @EASLedu #LiverTwitter @myESMO (Twitter) - Aug 24, 2022
- |||| lenvatinib / Generic mfg., sorafenib / Generic mfg.
Clinical: 🧐How to proceed with #HCC pts who deteriorate to CP B under Sorafenib or Lenvatinib❓ @TAMedOncol https://t.co/F4jTAzYJXP 📢We just published data from REFLECT phs-III 👉Continuation of systemic therapy is a viable option❗️ @EASLedu #LiverTwitter @myESMO (Twitter) - Aug 24, 2022
- | lenvatinib / Generic mfg.
Journal: Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma. (Pubmed Central) - Aug 24, 2022
Moreover, lenvatinib, an FDA recently approved multi-kinase inhibitor targeting both VEGFR2 and FGFR1, effectively inhibits the tumor vasculature, and exhibited robust anti-tumor effects in NPC-bearing nude mice and humanized mice compared with an agent equivalent to bevacizumab. These findings provide mechanistic insights on FGF-2 signaling in the modulation of VEGF pathway activation in the NPC microenvironment and propose an effective NPC-targeted therapy by using a clinically available drug.
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Review, Journal, PD(L)-1 Biomarker, IO biomarker: The Liver Cancer Immune Microenvironment: Therapeutic Implications for Hepatocellular Carcinoma. (Pubmed Central) - Aug 24, 2022
Half of the patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib, as a first-line therapy...In 2020, the combination of atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF) improved overall survival over sorafenib, resulting in FDA approval as a first-line treatment for advanced HCC patients...Other immune targeting-strategies, such as adoptive T-cell transfer, vaccination, or virotherapy, are currently under development. This review provides an overview on the HCC immune microenvironment, the different cellular players, the current available immunotherapies, and potential immunotherapy modalities.
- || Review, Journal: Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario. (Pubmed Central) - Aug 24, 2022
First-line systemic therapy options for unresectable or metastatic HCC include sorafenib, lenvatinib, and atezolizumab + bevacizumab. Regorafenib or cabozantinib provide survival benefits when given as second-line treatment.
- || everolimus / Generic mfg., lenvatinib / Generic mfg.
P2 data, Journal: Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. (Pubmed Central) - Aug 24, 2022
Regorafenib or cabozantinib provide survival benefits when given as second-line treatment. The study findings support the approved dosing regimen of lenvatinib 18 mg plus everolimus 5 mg daily for patients with advanced RCC.
- | lenvatinib / Generic mfg.
Retrospective data, Journal: Changes in Body Composition Predict the Time to Treatment Failure of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma: A Pilot Retrospective Study. (Pubmed Central) - Aug 24, 2022
This study revealed that LEN treatment induces a change in the skeletal muscle asymptomatically for a short period, and evaluation of this change may help to predict the TTF of LEN treatment in patients with HCC. Supplemental data for this article is available online at https://doi.org/10.1080/01635581.2022.2049322 .
- | Journal, Checkpoint inhibition: Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. (Pubmed Central) - Aug 24, 2022
ICI/TKI combination therapy is feasible and safe beyond the first-line setting. Prior treatment history appears to impact efficacy but has a lesser effect on safety/tolerability.
- | lenvatinib / Generic mfg.
Retrospective data, Journal, Real-world evidence: Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study. (Pubmed Central) - Aug 22, 2022
Thus, it may be a promising treatment for advanced HCC. Future prospective studies confirming these findings are warranted.
- || lenvatinib / Generic mfg., sorafenib / Generic mfg.
Review, Journal: Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment. (Pubmed Central) - Aug 22, 2022
Sarcopenia is associated with poor clinical outcomes in patients of HCC receiving sorafenib or lenvatinib. The MS score, based on the positivity of three prognostic factors, including skeletal MM, in patients receiving sorafenib, can be a reliable indicator of prolonged survival.
- | lenvatinib / Generic mfg.
Journal: Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy. (Pubmed Central) - Aug 22, 2022
LEN-TACE sequential therapy may provide more clinical benefits than LEN monotherapy in u-HCC patients who responded to initial LEN treatment. Objective response according to mRECIST to initial LEN is an independent factor contributing to LEN-TACE sequential therapy deep response.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: LEADER-001: Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma (clinicaltrials.gov) - Aug 22, 2022
P2, N=46, Recruiting, Sponsor: The First Hospital of Jilin University
- || lenvatinib / Generic mfg.
Review, Journal: Successful treatment with lenvatinib in a patient with thymic carcinoma presenting with cardiac tamponade: a case report and review of literature. (Pubmed Central) - Aug 22, 2022
Herein, we present a case of successful treatment with lenvatinib in a patient with TC presenting with cardiac tamponade. The present case suggests that lenvatinib should be considered an effective treatment option for such cases.
- Human Chart Abstraction Combined With Electronic Medical Record Programmed Queries Improves Identification of Patients With Cardiac Implanted Electronic Devices (Zone 3, Science and Technology Hall, Level 200) - Aug 20, 2022 - Abstract #AHA2022AHA_5946;
The present case suggests that lenvatinib should be considered an effective treatment option for such cases. Abstract is embargoed at this time.
- tremelimumab (CP-675206) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
CIO Abstract: Transarterial Chemoembolization ± (Tremelimumab and Durvalumab ± Lenvatinib) in Hepatocellular Carcinoma: EMERALD-3 () - Aug 19, 2022 - Abstract #CIO2022CIO_99;
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
ATEZOLIZUMAB PLUS BEVACIZUMAB VERSUS LENVATINIB OR SORAFENIB IN NON-VIRAL UNRESECTABLE HEPATOCELLULAR CARCINOMA: AN INTERNATIONAL PROPENSITY SCORE MATCHING ANALYSIS (Plenary room «Roma») - Aug 19, 2022 - Abstract #ILCA2022ILCA_93;
Abstract is embargoed at this time. The present analysis conducted on a large number of advanced non-viral HCC patients showed for the first time that treatment with lenvatinib is associated with a significant survival benefit compared to atezolizumab plus bevacizumab, in particular in patients with NAFLD/ NASH-related HCC.
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer
Journal: Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for advanced gastric cancer patients with or without liver metastases in clinical trials. (Pubmed Central) - Aug 18, 2022
The present analysis conducted on a large number of advanced non-viral HCC patients showed for the first time that treatment with lenvatinib is associated with a significant survival benefit compared to atezolizumab plus bevacizumab, in particular in patients with NAFLD/ NASH-related HCC. Anti-PD-1 antibodies plus regorafenib or lenvatinib for AGC showed promising antitumor activity with a longer follow-up, irrespective of liver metastases status, despite a more immune suppressive tumor microenvironment in liver metastases.
- | lenvatinib / Generic mfg.
Preclinical, Journal, PD(L)-1 Biomarker, IO biomarker: siRNA targeting PD-L1 delivered with attenuated Salmonella enhanced the anti-tumor effect of lenvatinib on mice bearing Hepatocellular carcinoma. (Pubmed Central) - Aug 17, 2022
Furthermore, the combination treatment increased the number of granzyme B T cells, indicating a significantly improved anti-tumor immunity in mice. Therefore, this combination might be a potential novel strategy for HCC treatment.
- | lenvatinib / Generic mfg.
Journal: Contrast-enhanced ultrasonography for blood flow detection in hepatocellular carcinoma during lenvatinib therapy. (Pubmed Central) - Aug 17, 2022
Therefore, this combination might be a potential novel strategy for HCC treatment. The viability of the HCC should be confirmed using CEUS when contrast-enhanced CT/MRI reveals lesion hypoenhancement during lenvatinib therapy.
- | lenvatinib / Generic mfg.
Retrospective data, Journal, Real-world evidence, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker: Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China. (Pubmed Central) - Aug 17, 2022
Lenvatinib plus PD-1 antibody treatment shows an active trend towards improving survival in patients with advanced BTCs after failure with CisGem chemotherapy. The treatment-related AEs are worthy of attention and are manageable.